Результаты поиска

Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison.

Emerging tumor immunotherapy methods encompass bispecific antibodies (BSABs), immune checkpoint inhibitors (ICIs), and adoptive cell immunotherapy. BSABs belong to the antibody family that can specifically recognize two different antigens or epitopes on the same antigen. These antibodies demonstrate superior clinical efficacy than monoclonal antibodies, indicating their role as a promising tumor immunotherapy option. Immune checkpoints are also important in tumor immunotherapy. Programmed cell death protein-1 (PD-1) is a widely acknowledged immune checkpoint target with effective anti-tumor ac

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.

The immune-cell origin of hematologic malignancies provides a unique avenue for the understanding of both the mechanisms of immune responsiveness and immune escape, which has accelerated the progress of immunotherapy. Several categories of immunotherapies have been developed and are being further evaluated in clinical trials for the treatment of blood cancers, including stem cell transplantation, immune checkpoint inhibitors, antigen-targeted antibodies, antibody-drug conjugates, tumor vaccines, and adoptive cell therapies. These immunotherapies have shown the potential to induce long-term rem

Совпадение в полном тексте источника
… CAR-T cells are designed to express CAR that aims to target specific tumor surface antigens with antigen specificity and HLA independence and is therefore not dependent on MHC (major histocompatibility complex) expression. …

Emerging Roles of Mesenchymal Stem/Stromal-Cell-Derived Extracellular Vesicles in Cancer Therapy.

Despite the tremendous efforts of many researchers and clinicians, cancer remains the second leading cause of mortality worldwide. Mesenchymal stem/stromal cells (MSCs) are multipotent cells residing in numerous human tissues and presenting unique biological properties, such as low immunogenicity, powerful immunomodulatory and immunosuppressive capabilities, and, in particular, homing abilities. Therapeutic functions of MSCs are mediated mostly by the paracrine effect of released functional molecules and other variable components, and among them the MSC-derived extracellular vesicles (MSC-EVs)

Совпадение в полном тексте источника
… Studies have shown that MSC-EVs include large numbers of transport proteins (tubulin, actin, and actin-binding molecules), as well as tetraspanins (CD9, CD63, CD81, and CD82), cell adhesion molecules (CAMs), major histocompatibility complex I (MHC-I) proteins, and integrins, which mediate cellular penetration …

Biopharmaceuticals for Cancer Treatment: An Update.

Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of specific pathways and the regulation of tumor markers. The approved cancer therapies demonstrate effectiveness by acting on specific regulatory enzymes, components required for cell division, hormones, and cell-specific receptors, etc. While small-molecule drugs

Совпадение в полном тексте источника
… Unlike traditional T cell responses, CARs recognize antigens without relying on the major histocompatibility complex (MHC), enabling potent T cell activation and strong anti‐tumor effects [ 161 ]. …

Canine Multicentric Lymphoma: Diagnostic, Treatment, and Prognostic Insights.

Lymphoma accounts for 24% of all documented canine neoplasms and 85% of hematological malignancies, while multicentric lymphoma corresponds to 84% of all canine lymphomas. Canine lymphomas of B-cell origin account for 60% to 80% of lymphomas. Similar to humans, the histologic grade, architecture, as well as immunophenotype determination, are crucial. These lesions are the most prevalent spontaneous tumors in dogs and this species may be a valuable animal model for the study of human non-Hodgkin's lymphoma. Therefore, it is important to investigate and assess therapeutic responses and to seek p

Совпадение в полном тексте источника
… CARs operate in a major histocompatibility complex (MHC)-independent manner, do not depend on patients’ antigen-presenting cells (APCs) for antigen presentation and are not required to be syngeneic to the patient’s immune system [ 64 ]. …

Targeted Therapies for Multiple Myeloma.

Multiple myeloma continues to be a challenging disorder to treat despite improved therapies and the widespread use of proteasome inhibitors and immunomodulatory drugs. Although patient outcomes have improved, the disease continues to invariably relapse, and in the majority of cases, a cure remains elusive. In the last decade, there has been an explosion of novel drugs targeting cellular proteins essential for malignant plasma cell proliferation and survival. In this review, we focus on novel druggable targets leading to the development of monoclonal antibodies and cellular therapies against su

Совпадение в полном тексте источника
… CAR-T therapy involves the cultivation of T-cells harbouring a synthetic receptor directed against a tumour-associated antigen that is independent of the major histocompatibility complex [ 82 ]. …

Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy.

Liver cancer, which most commonly manifests as hepatocellular carcinoma (HCC), is the sixth most common cancer in the world. In HCC, the immune system plays a crucial role in the growth and proliferation of tumor cells. HCC achieve immune escape through the tumor microenvironment, which significantly promotes the development of this cancer. Here, this article introduces and summarizes the functions and effects of regulatory T cells (Tregs) in the tumor microenvironment, highlighting how Tregs inhibit and regulate the functions of immune and tumor cells, cytokines, ligands and receptors, etc, t

Совпадение в полном тексте источника
… A key advantage of CAR-T therapy in treating hepatocellular carcinoma is that its efficacy does not rely on antigen presentation by major histocompatibility complex (MHC) molecules, thus circumventing MHC-related restrictions and addressing tumor immune escape issues due to MHC downregulation ( 79 ). …

Novel therapeutic strategies targeting resistance mechanisms in hematologic malignancies: from BCL2 inhibition to immunomodulatory approaches.

BACKGROUND: Hematologic malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma (MM), are characterized by high relapse rates due to intrinsic and acquired drug resistance. Resistance mechanisms often involve dysregulation of apoptosis pathways, such as B-cell lymphoma 2 (BCL2) family overexpression, and immune evasion through microenvironment modulation. PURPOSE: This review synthesizes recent advances (2020-2025) in therapeutic strategies targeting these mechanisms, focusing on BCL2 inhibition and immunomodul

Совпадение в полном тексте источника
… HMA: hypomethylating agents; APC: antigen-presenting cell; MHC: Major histocompatibility complex. Copy right from J Hematol Oncol. 2022 Aug 31; 15(1):124. ( Mohty et al., 2022 ). …

Навигация терапевтического ландшафта миеломы: иммунотерапия, микроокружающая среда и сопротивление.

Иммунотерапии, включая клетки химерика антигенного рецептора (CAR) T, биконкретные Т-клеточные агенты (BITEs) и антитело-наркотики (ADC), изменили ландшафт лечения множественной миеломы (MM). Несмотря на высокие показатели первоначальных ответов, достижение долговременной ремиссии по-прежнему сопряжено с трудностями из-за частых рецидивов, вызванных комплексными механизмами терапевтического сопротивления. В этом обзоре мы всесторонне исследуем врожденную устойчивость к опухоли, такую, как врожденный и приобретенный антигенный выход, обусловленный геномными изменениями, структурными вариациями

Совпадение в полном тексте источника
… Chimeric Antigen Receptor (CAR) T Cells Chimeric antigen receptor (CAR) T cells are autologous or allogeneic T cells genetically engineered to express synthetic receptors that recognize tumor-associated antigens independently of major histocompatibility complex (MHC)-mediated antigen presentation [ …

Форимтамиг, роман GPRC5D-targeting Антитела с клеточными клетками 2+1 Формат для лечения множественной миеломы.

Несмотря на несколько утвержденных методов лечения, миелома (ММ) остается неизлечимым заболеванием с высоким уровнем неудовлетворенных медицинских потребностей. 5 Член D (GPRC5D) продемонстрировал высокий уровень объективной реакции у пациентов, прошедших тщательное предварительное лечение, с MM; однако часто происходят первичное сопротивление, непродолжительная продолжительность реагирования и рецидив, вызванный сменой антигена. Хотя GPRC5D представляет собой наиболее избирательный целевой показатель в MM, недавние выводы показывают, что потери антигенов происходят чаще, чем в BCMA. Так, anti

Совпадение в полном тексте источника
… Considering the potential of PIs to induce immunogenic cells enhancing major histocompatibility complex class I–dependent T-cell responses, we identified PIs as promising combination partners for highly potent TCBs such as forimtamig. 48 , 49 Although our results provide only limited mechanistic insights …

Advances in cancer immunotherapy: Strategies and innovations strategies for adoptive immunotherapy of cancer.

Cancer immunotherapy has emerged as a transformative approach in oncology, offering alternatives beyond traditional treatments. This narrative review focuses on major innovations, including adoptive cell therapy (ACT), chimeric antigen receptor T-cells (CAR-T), T-cell receptor (TCR) engineering, monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and immune checkpoint inhibitors (ICIs). The central aim of this article is to analyze how these technologies improve antitumor responses and help overcome resistance in hematologic and solid tumors. This narrative review combines the latest

Совпадение в полном тексте источника
… Table 1 Comparison of characteristics between ICI, CAR T-CELL, and BiTE therapy (157-159) ICI: immune checkpoint inhibitor, CAR: chimeric antigen receptor, BiTE: bispecific T cell engager, CRS: cytokine release syndrome, MHC: major histocompatibility complex, TCR: T-cell receptor, scFv: single-chain …

Immunomodulatory effects of exercise in cancer prevention and adjuvant therapy: a narrative review.

Successful application of cancer immunotherapy has rekindled hope in cancer patients. However, a number of patients are unresponsive to immunotherapy and related treatments. This unresponsiveness in cancer patients toward different treatment regimens can be mainly attributed to severe immune dysfunction in such patients. Several reports indicate that physical exercise can significantly lead to improved cancer patient outcomes. Since exercise gets immense response from the immune system, it can be utilized to improve immune function. Leukocytes with enhanced functions are substantially mobilize

Совпадение в полном тексте источника
… Unlike their healthy counterparts, transformed tumor cells are often found to express ligands like major histocompatibility complex (MHC) class 1 chain–related proteins A and B (MICA and MICB) ( Garcia-Cuesta et al., 2015 ). …

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM). Importantly, the outcome of patients continues to improve with the incorporation of this new class of agents with current MM therapies. However, both antigens are also expressed on other normal tissues including hematopoietic lineages and immune effector cells, which may limit their long-term clinical use. B cell maturation antigen (BCMA), a transme

Совпадение в полном тексте источника
… Unlike T cell receptor modified T cells, CAR T cells are not restricted by major histocompatibility complex ( 40 ). …

Cardiovascular toxicities associated with novel cellular immune therapies.

AbstractOver the past decade, T-cell-directed therapies, including chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (BTE) therapies, have reshaped the treatment of an expanding number of hematologic malignancies, whereas tumor-infiltrating lymphocytes, a recently approved cellular therapy, targets solid tumor malignancies. Emerging data suggest that these therapies may be associated with a high incidence of serious cardiovascular toxicities, including atrial fibrillation, heart failure, ventricular arrhythmias, and other cardiovascular toxicities. The development of these

Integrated genomic and clinical modeling for prognostic assessment of radiotherapy response in rectal neoplasms.

The aim of this study is to develop a prognostic model for evaluating radiotherapy response in patients diagnosed with rectal neoplasms by integrating genomic and clinical data. Publicly accessible datasets from The Cancer Genome Atlas and Gene Expression Omnibus were analyzed to identify differentially expressed genes associated with drug resistance and mitophagy. Functional enrichment analyses were conducted to investigate relevant biological pathways. A prognostic risk model was constructed using least absolute shrinkage and selection operator regression and validated via receiver operating

Совпадение в полном тексте источника
… The degree of immunogenicity is influenced by multiple genetic factors, including those associated with effector cells, major histocompatibility complex molecules, immunomodulatory pathways, and immunosuppressive cellular components. …

Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma.

Bispecific antibodies (BsAbs) are artificially engineered antibodies that can bind simultaneously to the CD3 subunit within the T-cell receptor complex and an antigen on tumor cells, leading to T-cell activation and tumor cell killing. BsAbs against BCMA or GPRC5D have shown impressive clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), with some agents having already received regulatory approval after the third (by the European Medicines Agency, EMA) or fourth (by the Food and Drug Administration, FDA) line of therapy; the results of early-phase

Совпадение в полном тексте источника
… Notably, this immunomodulatory effect is not dependent on antigen presenting cells or major histocompatibility complex (MHC), and this aspect is noteworthy in the context of a dysfunctional immune system related to MM [ 13 , 14 , 15 ]. …

Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines.

Peptide-based vaccines only contain peptide epitopes and exclude unnecessary biological materials, which greatly reduces the risk of causing an undesired immune response and further improves the safety profile, garnering considerable interest in vaccine development. However, the immunogenicity induced by these peptides alone is not potent enough to elicit an effective immune response. Recently, combining the adjuvants with peptide antigens has shown promising effects to realize a satisfying immune response. In this review, we discuss the development of immunoadjuvants to enhance the safety and

Совпадение в полном тексте источника
… In their study, the P5 peptide, which contained a major histocompatibility complex (MHC) class I restricted multi-epitope derived from the rat human epidermal growth factor receptor 2 (HER2)/neu protein, was conjugated with Maleimide-PEG2000-DSPE and incorporated into liposomes along with the adjuvant …

B-cells in pulmonary arterial hypertension: friend, foe or bystander?

There is an unmet need for new therapeutic strategies that target alternative pathways to improve the prognosis of patients with pulmonary arterial hypertension (PAH). As immunity has been involved in the development and progression of vascular lesions in PAH, we review the potential contribution of B-cells in its pathogenesis and evaluate the relevance of B-cell-targeted therapies. Circulating B-cell homeostasis is altered in PAH patients, with total B-cell lymphopenia, abnormal subset distribution (expansion of naïve and antibody-secreting cells, reduction of memory B-cells) and chronic acti

< < Элотузумаб > > CD16-Independent NK Спутниковая цитотоксичность против ячеек миеломы путем регулирования нескольких NK-подкрепляющих генов

Множественная миелома (ММ) — неразрешимая гематологическая порча, вызванная аномалиями в плазменных клетках. Комбинированная терапия с использованием антител и эффектов естественного убийцы (НК), которые являются врожденными иммунными клетками с безопасной и мощной антитумбурной активностью, является перспективным подходом к онкологической иммунной терапии и может усилить антитумберные эффекты. Elotuzumab (Elo) — антитело с иммунной оптимистикой, предназначенное для семейства молекул лимфоцитной активации. 7 (SLAMF7) на поверхности клеток MM и NK. Мы подтвердили, что Эло активно пропагандирует

Совпадение в полном тексте источника
… NK cells are key immune cells with a large granular lymphoid population (CD56 + and/or CD16 + , CD3 − ) that have an innate ability to destroy tumor cells as effectors do not require the recognition of major histocompatibility complex or human leukocyte antigen (HLA) molecules [ 7 ]. …

Воздействие лечения на стероидом у женщин с множественным склерозом.

Множественный склероз (MS) — хроническое воспалительное нейродегенеративное заболевание центральной нервной системы. Происхождение MS связано с стероидными изменениями во время менструального цикла и беременности. Поскольку данных о воздействии лечения противомоскитных препаратов на стероидом недостаточно, мы провели оценку стерейдомичных изменений (79 стероидов) у 61 женщины-психолога репродуктивного возраста 39 лет (29, 47 лет) после лечения с помощью антимиосных препаратов на платформе GC-MS/MS и иммуномассы (кортизол и эстрадиол). Эти изменения были оценены с использованием уровней стероид

Совпадение в полном тексте источника
… GA blocks peptide-major histocompatibility complex and exerts its anti-inflammatory effect by affecting antigen-presenting cells (APCs) to promote the development of Th2 and production of anti-inflammatory cytokines (IL-4, IL-13, and IL-10) and, consequently, suppressing the development of pathogenic …